Circulating exosomal miR‐363‐5p inhibits lymph node metastasis by downregulating PDGFB and serves as a potential noninvasive biomarker for breast cancer

Sentinel lymph node (LN) biopsy is currently the standard procedure for clinical LN‐negative breast cancer (BC) patients but it is prone to false‐negative results and complications. Thus, an accurate noninvasive approach for LN staging is urgently needed in clinical practice. Here, circulating exosomal microRNA (miRNA) expression profiles in peripheral blood from BC patients and age‐matched healthy women were obtained and analyzed. We identified an exosomal miRNA, miR‐363‐5p, that was significantly downregulated in exosomes from plasma of BC patients with LN metastasis which exhibited a consistent decreasing trend in tissue samples from multiple independent datasets. Plasma exosomal miR‐363‐5p achieved high diagnostic performance in distinguishing LN‐positive patients from LN‐negative patients. The high miR‐363‐5p expression level was significantly correlated with improved overall survival. Functional assays demonstrated that exosomal miR‐363‐5p modulates platelet‐derived growth factor (PDGF) signaling activity by targeting PDGFB to inhibit cell proliferation and migration. Our study revealed, for the first time, plasma exosomal miR‐363‐5p plays a tumor suppressor role in BC and has the potential for noninvasive LN staging and prognosis prediction of BC.